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Abstract: Geraniol (GR) is an acyclic monoterpene alcohol present in essential oils of aromatic plant species used in Brazilian folk 
medicine for the treatment of epilepsy. The present study was designed to evaluate the anticonvulsant effect of GR and of the inclusion 
complex geraniol:β-cyclodextrin (GR:β-CD). Mice were treated with GR or with GR:β-CD (50, 100 and 200 mg/kg) 30 min before 
pentylenetetrazole (PTZ) or strychnine (STN). GR at 200 mg/kg and GR:β-CD at the doses of 100 and 200 mg/kg significantly increased the 
latency for the first PTZ-induced convulsion and reduced the percentage of animals that convulsed. The pretreatment of flumazenil did not 
revert the anticonvulsant effect of GR in the PTZ-induced convulsion model. In the STN-induced convulsion model, the effects of GR were 
investigated and no difference was found against control. The results demonstrated an anticonvulsant activity of GR in the PTZ-model, 
which was potentialized by the complexation with β-CD. 
 
Keywords: Epilepsy, Monoterpene, Pentylenetetrazole, Neuroprotective effect. 
 
RESUMEN: Geraniol (GR) es un alcohol monoterpeno acíclico presentes en los aceites esenciales de las especies de plantas aromáticas 
utilizadas en la medicina popular brasileña para el tratamiento de la epilepsia. El presente estudio fue diseñado para evaluar el efecto 
anticonvulsivo del GR y de la inclusión de geraniol complejo: β-ciclodextrina (GR:β-CD). Los ratones fueron tratados con GR o con GR:β-
CD (50, 100 y 200 mg/kg) 30 minutos antes de pentylenotetrazole (PTZ) o strichinine (STN). GR a 200 mg/kg y GR:β-CD en las dosis de 
100 y 200 mg/kg aumentó significativamente la latencia para la primera convulsión inducida PTZ-y redujo la porcentaje de animales que 
convulsionó. El tratamiento previo de flumazenil no revirtió el efecto anticonvulsivo de GR en el modelo de convulsión inducida con PTZ. 
En el modelo de convulsión inducida com STN, los efectos de GR fueron investigados y no se encontró ninguna diferencia contra el control. 
Los resultados demostraron una actividad anticonvulsiva de geraniol en el modelo de PTZ, que fue potenciada por la formación de 
complejos con β-CD. 
 
Palabras clave: Epilepsia, Monoterpenos, Pentilentetrazol, Efecto Neuroprotector. 
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INTRODUCTION 
Epilepsy is one of the most common neurological 
disorders, affecting about 50 million people 
worldwide. Usually, it is defined as a tendency to 
recurrent seizures that are caused by an abnormal 
discharge of cerebral neurons. Presently, seizures are 
viewed as electromagnetic discharges in the brain in 
predisposed individuals, attributable in part to 
putative genetic factors, underlying neurological 
disorders, and largely unknown neurochemical 
mechanisms (Loscher, 1998; WHO, 2005). 
 Traditionally, pharmacological strategies for 
the treatment of epilepsy have aimed at suppressing 
initiation or propagation of seizures rather than the 
processes leading to epilepsy (Loscher, 1998; 
Loscher & Schimidit, 2002). Currently available 
antiepileptic drugs have limited efficacy and their 
adverse effects limit their use and cause difficulties in 
patient management (Wahab, 2010). Thus, in the last 
years, a major goal in epilepsy research has been to 
develop antiepileptic drugs with higher 
anticonvulsant efficacy and less toxicity than the 
existing drugs (Loscher, 2002). 
 Plant extracts can be an important source for 
the development of more efficient and safer drugs for 
the treatment of epilepsy (Wahab et al., 2009). The 
pharmacological use of the plants is mainly attributed 
to their essential oils’ having a great variety of 
pharmacological activities, including anticonvulsant 
activity (Quintans-Junior et al., 2008; Almeida et al., 
2011; Koutroumanidou et al., 2013; Shareef et al., 
2013). The biological properties of essential oils are 
attributed to the monoterpenes, which are their main 
chemical constituents (Sousa et al., 2006; Almeida et 
al., 2011). Previous studies in animal experiments 
evidenced the anticonvulsant activity of some 
monoterpenes present in various essential oils, such 
as linalool (Elisabetsky et al., 1995), citronellol 
(Sousa et al., 2006), citronellal (Melo et al., 2011), 
carvacrol, borneol and citral (Quintans-Junior et al., 
2010). 
 Geraniol (GR) is an acyclic monoterpene 
alcohol (Figure 1) referred to as a mixture of two 
isomers properly named geraniol (trans) and nerol 
(cis). GR is a common constituent of several essential 
oils and exhibits various biochemical and 
pharmacological properties (Chen & Viljoen, 2010). 
However, it is practically insoluble in water, like 
many of the newly discovered drugs. Water solubility 
is an important determinant of therapeutic 
effectiveness of a drug, since it plays an important 
role in bioavailability (Lapczynski et al., 2008; 
Zaheer et al., 2011). 
 
Fig. 1 
 
 
Figure 1 
Chemical structures of geraniol and nerol 
 
Cyclodextrins (CD) are cyclic 
oligosaccharides used in the pharmaceutical industry 
as complexing agents to increase aqueous solubility 
of poorly soluble drugs and to increase their 
bioavaibility and stability (Marreto et al., 2008; 
Rasheed et al., 2008; Hadaruga et al., 2012; Serafini 
et al., 2012). The β-cyclodextrin (β-CD) appears to 
be the most useful pharmaceutical complexing agent 
because of its complexing efficiency, with extremely 
low toxicity and capacity of enhancing drug delivery 
through biological membranes. Furthermore, it has 
low cost (Loftsson & Masson, 2001). 
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 Since there is no data about the possible 
anticonvulsant effect of GR, the aim of this study was 
to evaluate its anticonvulsant activity and of the 
inclusion complex geraniol:β-CD (GR:β-CD), in two 
animal convulsion models. 
 
MATERIALS AND METHODS 
Animals 
One hundred fifty-seven with 2-3 months male Swiss 
mice (25-35 g) were used. All animals were housed 
in groups of 8-10 per cage (30 cm x 37 cm x 16 cm) 
under condictions of acoustic isolation and controlled 
airflow and temperature (25 ± 1º C), with a 12 h 
light/12 h dark cycle (lights on 6:00 a.m.).  Food and 
water were available ad libitum. Animals used in this 
study were handled in accordance with the guidelines 
of the Brazilian law for the use of animals in research 
(Law Number 11.794) and all procedures were 
approved by the local ethics committee (Animal Care 
and Use Committee of the Federal University of 
Sergipe - CEPA/UFS Number 84/2011. All efforts 
were made to minimize animal pain, suffering or 
discomfort. 
 
Chemicals 
Pentylenetetrazole (PTZ), Strychinine (STN), 
Geraniol 98% (GR), β-cyclodextrin (β-CD), 
Polyoxyethylene-sorbitan monolated (Tween 80) 
were purchased from Sigma Chemical Company (St 
Louis, MO., USA).  Diazepam (DZP) and Flumazenil 
(FLU) was obtained from União Química, Pouso 
Alegre, MG, Brazil). All the drugs were administered 
by the intraperitoneal route (ip) at a final volume of 
0.1 mL/10 g body weight of mice. 
 
Preparation of the inclusion complex 
The inclusion complex, GR:-CD, was prepared by 
the slurry procedure. Slurry complexation was carried 
out by the addition of distilled water until the 
completion of 126 mL to a beaker containing 1.135 g 
of -CD (3:4, v/w) and GR (154 mg), equal to about 
a 1:1 molar guest- host ratio, was added to the slurry 
and stirred for 36 h by a magnetic stirring device 
operating at 400 rpm. Thereafter, the mixture was 
heated to 70 °C for 2 h in the same device, transferred 
to an agate mortar, and dried in a desiccator 
(Menezes et al., 2012). 
 
 
 
 
Convulsions tests 
Pentylenetetrazole (PTZ)-induced convulsion test  
PTZ, at the dose of 60 mg/kg, was injected in mice 
for induction of tonic-clonic convulsions (Fisher, 
1989). It is well established that GR has low acute 
toxicity in mammals (Lapczynski et al., 2008; Chen 
& Viljoen, 2010). Therefore, the selected doses of 
GR were based in other studies about anticonvulsant 
effects of monoterpenes (Silva et al., 2009; Quintans-
Junior et at., 2010). Mice were divided into five 
groups (8-12 mice per group), the first group served 
as control and received vehicle (saline), while the 
second group was treated with DZP (2 mg/kg, ip). 
The remaining groups received GR (50, 100 and 200 
mg/kg, ip). After 30 min of drug administration, mice 
were treated with PTZ. Experiments were repeated 
following the pretreatment with the complex GR:β-
CD (50, 100 and 200 mg/kg, ip) or saline, 30 min 
prior to the administration of PTZ. Animals were 
transferred to individual cages and (1) the latency for 
the first convulsion, (2) the number of animals 
convulsing and (3) the number of the deaths were 
observed for 15 min. (as in Vasconcelos et al., 2007; 
Melo et al., 2011). The ability of GR or the inclusion 
complex GR:β-CD to prevent or delay the onset of 
convulsions was taken as an indication of 
anticonvulsant activity. Mice that did not show any 
tonic-clonic convulsion within 15 min of PTZ 
administration were considered protected 
(Vasconcelos et al., 2007; Quintans-Junior et al., 
2008).  
 
Strychinine-induced convulsion test 
Strychinine (STN) convulsions followed by death 
were shown to occur in animals by the injection (ip) 
of 3 mg/kg of the STN (Oliveira et al., 2009). The 
mice were pretreated with GR (50, 100 or 200 mg/kg, 
ip) or saline (control group) 30 min before the 
administration (ip) of STN (n = 6 per group). After 
that, they were placed in individual cages and (1) the 
latency for the first convulsion, (2) the number of 
animals convulsing and (3) the number of the deaths 
were observed for 15 min.  
 
Mechanisms involved in the anticonvulsant effect of 
Geraniol  
To investigate the possible mechanisms underlying 
the anticonvulsant activity of GR, the animals were 
pretreated with flumazenil (FLU, 5 mg/kg, ip) an 
antagonist of GABAA/benzodiazepine receptors 
(Savié et al., 2004). The animals were first 
administered with FLU, 20 min later, with GR (200 
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mg/kg), and 30 min after GR, with PTZ (60 mg/kg). 
Behavioral changes (1) the latency for the first 
convulsion, (2) the number of animals convulsing and 
(3) the number of the death were observed. 
 
Statistical analysis 
The data obtained from latencies for the first 
convulsion were analyzed using the Kolmogorov-
Smirnov test for normal distributions and by Bartlett's 
test for homogeneity of variances. Then, data were 
evaluated by analysis of variance (one-way ANOVA) 
followed by Tukey’s test. The incidence (%) of 
clonic or tonic-clonic convulsions as well as the 
mortality were evaluated by the Fisher’s Exact Test. 
Results are expressed as mean ± S.E.M. and p < 0.05 
was considered to reflect significant differences. All 
statistical analyses were performed using Graph Pad 
Prism 5.0 (Graph Pad Prism Software Inc., San 
Diego, CA, USA). 
 
Fig. 2 
 
Figure 2 
Effect of geraniol (GR) and inclusion complex GR:β-CD on the latency to convulsions induced by 
pentylenetetrazole (PTZ; 60 mg/kg). (A) Saline, GR (50, 100 and 200 mg/kg), DZP (2 mg/kg), (B) Saline, 
GR:β-CD (50, 100 and 200 mg/kg), DZP (2 mg/kg) were administered ip 30 min before PTZ. One way 
ANOVA revealed statistically signiﬁcant difference between groups. Geraniol increases the latency to PTZ-
induced convulsions. Data are expressed as mean ± S.E.M. (n = 8-12 per group). Statistically significant 
differences 
a
p < 0.05 comparing to Saline; 
b
p < 0.05 comparing to GR 50 mg/kg; 
c
p < 0.05 comparing to GR 
100 mg/kg (Tukey’s post hoc test) 
 
RESULTS 
Geraniol at 200 mg/kg delays onset of PTZ-induced 
convulsions 
In respect to latency to the tonic-clonic PTZ-induced 
convulsions, one-way ANOVA revealed a significant 
effect of treatment [F(4, 47) = 20.90, p < 0.001]. Post 
hoc analysis revealed an increase in the latency to 
convulsion in the GR 200 mg/kg group when 
compared to Saline (p < 0.001), GR 50 mg/kg (p < 
0.001) and GR 100 mg/kg groups (p = 0.047), but not 
when compared to the DZP group (p = 0.127), see 
Figure 2A. Fisher’s test revealed that a lower 
percentage of animals convulsed in the DZP and GR 
200 mg/kg groups when compared to the Saline 
group (p < 0.05), but not when compared to GR 50 
mg/kg and GR 100 mg/kg groups (see Table 1). 
Moreover, Fisher’s test revealed no difference in the 
frequency of mortality between groups. No deaths 
were registered in the groups treated with DZP 2 
mg/kg, GR 50 mg/kg, GR 100 mg/kg and GR 200 
mg/kg, see Table 1. 
 
Geraniol:β-cyclodextrin at 100 mg/kg delays onset 
of PTZ-induced convulsions  
In respect to latency to the tonic-clonic PTZ-induced 
convulsions, one-way ANOVA revealed a significant 
effect of treatment [F(4, 47) = 17.95, p < 0.001]. Post 
hoc analysis revealed an increase in latency for 
seizures in the GR:β-CD 100 mg/kg and GR:β-CD 
200 mg/kg groups when compared to Saline (p = 
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0.004 and 0.0001, respectively) and to GR:β-CD 50 
mg/kg  groups (p = 0.032 and 0.001, respectively). 
No difference was found between the DZP group and 
GR 200 mg/kg (p = 0.094) (see Figure 2B). Fisher’s 
test revealed that a reduced percentage of animals 
convulsed in the DZP, GR:β-CD 100 mg/kg and 
GR:β-CD 200 mg/kg groups when compared to 
Saline group (p < 0.05), but not when compared to 
GR:β-CD 50 mg/kg group (see Table 1). Moreover, 
Fisher’s test revealed that the pretreatment with DZP 
2 mg/kg, GR:β-CD 50 mg/kg, GR:β-CD 100 mg/kg 
and GR:β-CD 200 mg/kg completely protected the 
animals against the tonic-clonic convulsions induced 
by PTZ (p < 0.05), see Table 1.  
 
Table 1 
Effects of Geraniol (GR) and inclusion complex GR:β-cyclodextrin (GR:β-CD) on tonic-clonic seizures 
induced by PTZ. 
Treatment Dose (mg/kg) Convulsions (%) Mortality (%) 
Saline - 100 18 
DZP 2 0a 0 
GR 50 100 0 
GR 100 75 0 
GR 200 50a 0 
    
Saline - 100 16.6 
DZP 2 0a 0 
GR:β-CD 50 100 0 
GR:β-CD 100 66b 0 
GR:β-CD 200 50a 0 
N = 8-12, per group 
a p < 0.01 (Fisher’s test), significantly different from control 
b
 p < 0.05 (Fisher’s test), significantly different from control 
 
 
Geraniol has no effect on strychnine-induced 
convulsions 
One-way ANOVA revealed no effect of treatment 
[F(3, 19) = 0.39, p = 0.75] in the latencies to first 
convulsion in the strychnine convulsion model (see 
Figure 3). All mice in the control group presented 
convulsions and the pretreatment with GR failed to 
inhibit seizures and mortality (see Table 2). We did 
not use the standard control drug, phenytoin, in the in 
the STN-induced convulsion model because its 
actions are widely described in the literature. 
Moreover, as GR did not show positive effect, 
we believe that the insertion of a group with 
phenytoin would be an inappropriate use of 
animals. 
 
Geraniol anticonvulsant action is not antagonized 
by flumazenil 
One-way ANOVA revealed an effect of treatment 
[F(2, 28) = 28.26, p < 0.001] in the latencies to first 
convulsion in the tonic-clonic PTZ-induced 
convulsions model pre-treated with FLU (5 mg/kg), 
an antagonist of GABAA/benzodiazepine receptors. 
Post hoc analysis revealed an increase in the latency 
to convulsions in the GR 200 mg/kg (p < 0.001) and 
FLU + GR 200 mg/kg (p < 0.001) groups when 
compared to the Saline group, but no difference was 
found between GR 200 mg/kg and FLU+GR 200 
mg/kg (p = 0.226), see Figure 4. 
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Figure 3 
Effect of geraniol (GR) on the latency to convulsion induced by strychnine (STN-3 mg/kg). Saline, GR (50, 
100 and 200 mg/kg), DZP (2 mg/kg) were administered ip 30 min before STN. Data are expressed as mean ± 
SEM (n = 6 per group). 
 
 
 
Table 2 
Effects of Geraniol (GR) on tonic-clonic convulsions induced by Strychinine. 
Treatment Dose (mg/kg) Convulsions (%) Mortality (%) 
Saline - 100 100 
GR 50 100 100 
GR 100 100 100 
GR 200 100 100 
n = 6, per group 
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Figure 4 
Effect of pretreatment with Flumazenil (FLU) (5 mg/kg) on anticonvulsant effect of geraniol (200 mg/kg). 
FLU was administered ip 20 min before the GR (200mg/kg) and 50 min before the PTZ. One way ANOVA 
revealed statistically signiﬁcant difference between groups. Data are expressed as mean ± S.E.M. (n = 8 per 
group). Statistically significant differences 
ap < 0.05 comparing to Saline (Post hoc with Tukey’s test). 
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DISCUSSION 
Geraniol (GR) is an acyclic monoterpene alcohol 
present in essential oils of various plants, such as 
Cymbopogon winterianus Jowitt (Poaceae) 
(Quintans-Junior et al., 2008; Silva et al., 2010), 
Ocimum basilicum (Lamiaceae) (Oliveira et al., 
2009) and in other aromatic plant species (Silva et 
al., 2010), and studies have reported the 
anticonvulsant activity of these plants. In the present 
work, we investigated the anticonvulsant effect of GR 
and of the inclusion complex GR:β-CD in PTZ and 
STN-induced convulsions models, because these 
models are commonly used in preliminary screening 
tests for characterizing potential anticonvulsant 
drugs. 
 We reported that GR, at the dose 200 mg/kg 
delayed the onset of tonic-clonic convulsions in the 
PTZ model (Figure 2) and reduced the percentage of 
animals that convulsed (Table 1). Some studies have 
reported that others monoterpenes such as linalool 
(Elisabetsky et al., 1995), citronellol (Sousa et al., 
2006), citronellal (Melo et al., 2011), limonene, beta-
myrcene and citral (Viana et al., 2000), also showed 
anticonvulsant activity in PTZ-induced convulsions. 
The effects of the monoterpenes can occur through 
several mechanisms due to their structural diversity, 
once they can be acyclic or cyclic, and classified as 
alcohols, aldehydes, ketones and others. However, 
some monoterpenes have similar structures and could 
modulate the same receptors (Passos et al., 2009). 
 It is widely recognized that the PTZ 
mechanism of action is associated to the inhibition of 
the activity of gamma aminobutyric acid (GABA) at 
GABAA receptors (Fisher, 1989; De Sarro et al., 
1999; Fradley et al., 2007). GABA is the major 
inhibitory neurotransmitter in the brain and impaired 
GABAergic inhibitory neurotransmission is involved 
in the pathogenesis of several types of epilepsy 
(Loscher & Sshimidit, 2002). The enhancement and 
inhibition of GABA neurotransmission will attenuate 
or enhance seizures, respectively (Gale, 1992). 
Therefore, drugs that enhance GABAA receptor-
mediated activity potentially attenuate PTZ-induced 
convulsions, by either inhibiting seizures or 
increasing their latency to onset (Smith et al., 2007).  
 GR is practically insoluble in water 
(Lapczynski et al., 2008), a physical property which 
may impair its pharmacological action. Solubility is 
an important parameter for achieving the desired 
concentration of a drug in the systemic circulation so 
that pharmacological response can be observed 
(Zaheer et al., 2011). Cyclodextrins (CDs) are a 
family of cyclic oligosaccharides with a hydrophilic 
outer surface and a lipophilic central cavity. In the 
pharmaceutical industry they are used to enhance 
aqueous solubility and chemical stability of drugs 
(Zaheer et al., 2011). β-CD is the most used CD in 
pharmaceutical industry, because it is most accessible 
and the lowest-priced (Del Valle, 2004). The 
inclusion complex GR:β-CD used in our study was 
the same as used by Menezes et al. (2012), in which 
thermal analysis clearly indicated the formation of 
complex.  
Our results suggest that the inclusion of 
geraniol within β-CD molecule improved its 
bioavailability. We showed that GR:β-CD enhanced 
its anticonvulsant efficacy in the PTZ-induced 
convulsion model, since the inclusion complex GR:β-
CD showed anticonvulsant effect at doses 100 and 
200 mg/kg compared to GR which showed a 
significant effect only at a higher dose (200 mg/kg). 
Increased solubility might result in improved 
bioavailability, which increases pharmacological 
efficacy and allows a reduction in the dose of the 
drug administered (Del Valle, 2004).  
On the other hand, in the strychinine-induced 
convulsion test, GR did not prevent convulsions 
(Table 2) and did not alter latency to convulsion 
(Figure 4) when compared to controls. STN is a 
competitive glycine receptor antagonist, which 
increases postsynaptic excitability and ongoing 
activity in the brain stem and spinal cord (Webb & 
Lynch, 2007). Since GR did not prevent the 
convulsions induced by STN, our results suggest that 
involvement on glycinergic neurotransmission is 
unlikely. 
Since GR delayed the onset of PTZ 
convulsion in our study, it is probable that GR may 
be interfering with GABAergic mechanisms to exert 
its anticonvulsant effect. To determine whether the 
anticonvulsant effect of GR occurs through the 
GABAergic system, the animals were pretreated with 
flumazenil, a clinically used competitive antagonist 
that binds the benzodiazepine site of the GABAA 
receptor (Oliveira et al., 2009). Our results shown 
that the effect of GR was not significantly decreased 
by flumazenil pretreatment (Figure 5), at a dose that 
antagonizes the anticonvulsant effects of DZP (2 
mg/kg), suggesting that GR anticonvulsant effect 
does not involve the benzodiazepine site of the 
GABAA receptor. The same results were found by 
others studies that evaluated the anticonvulsant effect 
of others monoterpenes (Almeida et al., 2008; 
Quintans-Junior et al., 2010). 
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 In conclusion, the present data indicate an 
anticonvulsant activity of GR in the PTZ-induced 
convulsion model and the inclusion of GR and β-CD 
enhanced this effect. The precise mechanisms of the 
anticonvulsant effect of GR and the inclusion 
complex GR:β-CD are not clear, although our 
evidence points that GR anticonvulsant effect seems 
to be independent of benzodiazepine receptors. 
Nevertheless, further studies are needed for 
elucidating the mechanisms involved. 
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